Back to Results
First PageMeta Content
Medicine / Clinical medicine / Cancer / Melanoma / RTT / Uveal melanoma / Cancer treatments / Immunology / Oncology / Uvea / Immunocore / Cancer immunotherapy


PRESS RELEASE – IMMUNOCORE LIMITED Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma (Oxford, UK, 30 MarchImmunocore, a world-leading biotechnology company developing novel T cell
Add to Reading List

Document Date: 2016-03-29 05:35:06


Open Document

File Size: 413,56 KB

Share Result on Facebook